BioCentury
ARTICLE | Clinical News

Opaxio paclitaxel poliglumex: Phase III ongoing

February 9, 2015 8:00 AM UTC

The NCI’s Gynecologic Oncology Group (GOG) informed CTI that an independent DMC recommended for the second time continuation of the open-label, U.S. Phase III GOG-0212 trial of Opaxio based on the sec...